Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.

6504Background: HRAS is a proto-oncogene overexpressed and mutated in some human carcinomas. Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase, a critical enzyme for prop...